Tuberculosis subunit vaccines: from basic science to clinical testing

被引：25

作者：

Doherty, T. Mark ^{[1
]}

Dietrich, Jes ^{[1
]}

Billeskov, Rolf ^{[1
]}

机构：

[1] State Serum Inst, Dept Infect Dis Immunol, Copenhagen, Denmark

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 10期

关键词：

biomarker; clinical development; subunit vaccine; tuberculosis;

D O I：

10.1517/14712598.7.10.1539

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

More than 80 years after the introduction of Bacillus Calmette-Guerin, the first tuberculosis vaccine, new vaccines for tuberculosis are finally in clinical trials. The selection of antigens on which new subunit vaccines are based represent the first fulfilment of the promise of proteomics and genomics, and the delivery systems for these antigens are likewise the first fruits of the improved understanding of how the host immune system recognizes pathogens. However, clinical trials are still at Phase I and there remain formidable obstacles to the registration of the first new TB vaccines. Here the authors review the vaccines in clinical trials and discuss the different approaches they take to stimulating immunity to Mycobacterium tuberculosis infection, focusing on recombinant subunit vaccines. The challenges that confront these approaches and how they are being addressed are then discussed.

引用

页码：1539 / 1549

页数：11

共 77 条

[31] Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection [J].

Gomez-Reino, Juan J. ;

Carmona, Loreto ;

Descalzo, Miguel Angel .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (05) :756-761

[32] Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara [J].

Goonetilleke, NP ;

McShane, H ;

Hannan, CM ;

Anderson, RJ ;

Brookes, RH ;

Hill, AVS .

JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1602-1609

[33] Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen:: Importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy [J].

Grode, L ;

Kursar, M ;

Fensterle, J ;

Kaufmann, SHE ;

Hess, J .

JOURNAL OF IMMUNOLOGY, 2002, 168 (04) :1869-1876

[34] BCG AND VOLE BACILLUS VACCINES IN PREVENTION OF TUBERCULOSIS IN ADOLESCENCE AND EARLY ADULT LIFE - FINAL REPORT TO MEDICAL-RESEARCH-COUNCIL [J].

HART, PD ;

SUTHERLAND, I .

BRITISH MEDICAL JOURNAL, 1977, 2 (6082) :293-295

[35] Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells [J].

Havenga, M. ;

Vogels, R. ;

Zuijdgeest, D. ;

Radosevic, K. ;

Mueller, S. ;

Sieuwerts, M. ;

Weichold, F. ;

Damen, I. ;

Kaspers, J. ;

Lemckert, A. ;

van Meerendonk, M. ;

van der Vlugt, R. ;

Holterman, L. ;

Hone, D. ;

Skeiky, Y. ;

Mintardjo, R. ;

Gillissen, G. ;

Barouch, D. ;

Sadoff, J. ;

Goudsmit, J. .

JOURNAL OF GENERAL VIROLOGY, 2006, 87 :2135-2143

[36] Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs [J].

Hogarth, PJ ;

Jahans, KJ ;

Hecker, R ;

Hewinson, RG ;

Chambers, MA .

VACCINE, 2003, 21 (9-10) :977-982

[37] Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines [J].

Holten-Andersen, L ;

Doherty, TM ;

Korsholm, KS ;

Andersen, P .

INFECTION AND IMMUNITY, 2004, 72 (03) :1608-1617

[38] A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG [J].

Horwitz, MA ;

Harth, G ;

Dillon, BJ ;

Maslesa-Galic, S .

VACCINE, 2006, 24 (10) :1593-1600

[39] A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis [J].

Horwitz, MA ;

Harth, G .

INFECTION AND IMMUNITY, 2003, 71 (04) :1672-1679

[40] Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design [J].

Ibango, Hannah B. ;

Brookes, Roger H. ;

Hill, Philip C. ;

Owiafe, Patrick K. ;

Fletcher, Helen A. ;

Lienhardt, Christian ;

Hill, Adrian V. S. ;

Adegbola, Richard A. ;

McShane, Helen .

LANCET INFECTIOUS DISEASES, 2006, 6 (08) :522-528

← 1 2 3 4 5 6 7 8 →